GeoVax Executives to Pursue European Partnerships for Vaccine and Cancer Therapy Development
TL;DR
GeoVax executives are meeting with global health organizations and potential partners to secure collaborations that accelerate vaccine development and manufacturing for competitive market positioning.
GeoVax leadership will attend European conferences and conduct structured meetings with NGOs and academic collaborators to advance vaccine development through methodical partnership building.
GeoVax's partnership efforts aim to expand global access to critical vaccines for immunocompromised patients and advance cancer therapies to improve worldwide healthcare outcomes.
GeoVax is showcasing innovative vaccine platforms including Mpox prevention and novel cancer therapies while engaging with global health leaders across multiple European cities.
GeoVax Labs, Inc. senior leadership will participate in European meetings over the coming weeks to advance partnering and collaboration engagement across the company's portfolio of vaccines and immunotherapies. Chairman and Chief Executive Officer David A. Dodd and Vice President John Sharkey, PhD, together with other senior team members, will attend World Vaccine Congress Europe in Amsterdam from October 14-16, 2025, and BIO-Europe Fall in Vienna from November 3-5, 2025.
Beyond conference activities, the team will conduct meetings with global non-governmental organizations including WHO, UNICEF, CEPI, Gavi, and the Africa CDC, as well as established and prospective academic institutional collaborators across Europe. These engagements aim to solidify durable relationships that can accelerate development in support of expanded access to critical vaccines and immunotherapies.
David A. Dodd emphasized the strategic importance of these meetings, stating the company is engaging with global health leaders and prospective partners to align on near-term opportunities in mpox and smallpox preparedness, addressing the critically unmet needs of immunocompromised patients relative to COVID-19, expanding the development breadth of Gedeptin as neoadjuvant cancer therapy, and exploring complementary collaborations across their broader platform.
The partnering focus areas span GeoVax's pipeline and technology platforms, including GEO-MVA, their Mpox and smallpox vaccine candidate designed to accelerate access to a second-source of the critically needed vaccine with rapid, scalable manufacturing capabilities. The company's GEO-CM04S1 multi-antigen COVID-19 vaccine, designed to elicit robust T-cell and antibody responses, represents another priority area with focus on addressing the current unmet needs of an estimated over 400 million immunocompromised patients worldwide.
Gedeptin, the company's gene-directed enzyme prodrug therapy, offers a tumor-targeted immuno-oncology approach with potential combination synergies with checkpoint inhibitors, providing a potential new neoadjuvant therapy against solid tumors. Additional platform applications include hemorrhagic fever and Zika programs, continuous cell-line manufacturing, and potential technology-transfer collaborations.
Dr. John Sharkey noted that the company continues to receive compelling interest from governments, NGOs, and potential industry collaborators seeking diversified, resilient vaccine supply and clinically differentiated immunotherapies. The goal is to convert that interest into structured collaborations that accelerate development, manufacturing readiness, and regional availability. Additional information about GeoVax and its programs is available at https://www.geovax.com.
These European engagements represent significant opportunities for advancing global health initiatives through strategic partnerships. The potential collaborations could accelerate development timelines for critical vaccines and cancer therapies, potentially bringing important medical innovations to patients faster while strengthening global health security through diversified vaccine manufacturing capabilities.
Curated from NewMediaWire